GSK plc (NYSE:GSK) Shares Purchased by Enterprise Bank & Trust Co

Enterprise Bank & Trust Co grew its position in shares of GSK plc (NYSE:GSK) by 3.0% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 26,892 shares of the pharmaceutical company’s stock after purchasing an additional 791 shares during the period. Enterprise Bank & Trust Co’s holdings in GSK were worth $909,000 at the end of the most recent quarter.

Several other hedge funds have also modified their holdings of GSK. Eastern Bank acquired a new stake in shares of GSK in the third quarter worth approximately $26,000. ST Germain D J Co. Inc. raised its stake in shares of GSK by 195.5% during the fourth quarter. ST Germain D J Co. Inc. now owns 789 shares of the pharmaceutical company’s stock valued at $27,000 after purchasing an additional 522 shares during the period. Sunbelt Securities Inc. raised its stake in shares of GSK by 73.8% during the third quarter. Sunbelt Securities Inc. now owns 711 shares of the pharmaceutical company’s stock valued at $29,000 after purchasing an additional 302 shares during the period. Concord Wealth Partners increased its stake in shares of GSK by 231.8% in the third quarter. Concord Wealth Partners now owns 783 shares of the pharmaceutical company’s stock worth $32,000 after buying an additional 547 shares during the last quarter. Finally, Ashton Thomas Private Wealth LLC bought a new stake in shares of GSK in the second quarter worth $37,000. 15.74% of the stock is owned by institutional investors and hedge funds.

GSK Trading Down 1.1 %

NYSE GSK traded down $0.37 on Monday, hitting $32.72. 3,601,305 shares of the company were exchanged, compared to its average volume of 3,047,737. The company’s 50 day moving average price is $34.38 and its 200-day moving average price is $38.17. The company has a debt-to-equity ratio of 0.98, a current ratio of 0.81 and a quick ratio of 0.53. The firm has a market capitalization of $67.81 billion, a P/E ratio of 21.25, a price-to-earnings-growth ratio of 1.52 and a beta of 0.63. GSK plc has a twelve month low of $32.55 and a twelve month high of $45.92.

GSK Increases Dividend

The firm also recently announced a quarterly dividend, which was paid on Thursday, January 9th. Shareholders of record on Friday, November 15th were paid a dividend of $0.3928 per share. This represents a $1.57 annualized dividend and a yield of 4.80%. The ex-dividend date of this dividend was Friday, November 15th. This is a boost from GSK’s previous quarterly dividend of $0.38. GSK’s payout ratio is 95.45%.

Wall Street Analysts Forecast Growth

A number of equities analysts have commented on the stock. Guggenheim downgraded shares of GSK from a “buy” rating to a “neutral” rating in a report on Thursday, October 31st. StockNews.com raised shares of GSK from a “buy” rating to a “strong-buy” rating in a report on Monday. Jefferies Financial Group cut shares of GSK from a “buy” rating to a “hold” rating and cut their price objective for the company from $53.00 to $39.50 in a research note on Tuesday, November 12th. Finally, Deutsche Bank Aktiengesellschaft cut shares of GSK from a “buy” rating to a “hold” rating in a research report on Friday, November 15th. Seven analysts have rated the stock with a hold rating and four have given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $43.25.

About GSK

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.